BIAF
bioAffinity Technologies, Inc.
NASDAQ: BIAF · HEALTHCARE · DIAGNOSTICS & RESEARCH
$2.49
+2.26% today
Updated 2026-04-30
Market cap
$10.03M
P/E ratio
—
P/S ratio
1.63x
EPS (TTM)
$-8.66
Dividend yield
—
52W range
$1 – $15
Volume
10.8M
bioAffinity Technologies, Inc. (BIAF) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-2.49M | $-2.21M | $-2.05M | $-4.07M | $-6.04M | $-7.26M | $-9.33M |
| Capital expenditures | $11404.00 | $2888.00 | $0.00 | $219987.00 | $22902.00 | $79083.00 | $60568.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $275732.00 | $43012.00 | $248592.00 | $748823.00 | $989681.00 | $671474.00 |
| Free cash flow | $-2.50M | $-2.21M | $-2.05M | $-4.29M | $-6.06M | $-7.34M | $-9.39M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $185.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |